1. Home
  2. TSLX vs MESO Comparison

TSLX vs MESO Comparison

Compare TSLX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSLX
  • MESO
  • Stock Information
  • Founded
  • TSLX 2010
  • MESO 2004
  • Country
  • TSLX United States
  • MESO Australia
  • Employees
  • TSLX N/A
  • MESO N/A
  • Industry
  • TSLX Investment Managers
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TSLX Finance
  • MESO Health Care
  • Exchange
  • TSLX Nasdaq
  • MESO Nasdaq
  • Market Cap
  • TSLX 2.2B
  • MESO 2.0B
  • IPO Year
  • TSLX 2014
  • MESO N/A
  • Fundamental
  • Price
  • TSLX $23.49
  • MESO $16.37
  • Analyst Decision
  • TSLX Strong Buy
  • MESO Buy
  • Analyst Count
  • TSLX 7
  • MESO 4
  • Target Price
  • TSLX $22.79
  • MESO $18.00
  • AVG Volume (30 Days)
  • TSLX 417.3K
  • MESO 255.7K
  • Earning Date
  • TSLX 02-13-2025
  • MESO 03-04-2025
  • Dividend Yield
  • TSLX 8.86%
  • MESO N/A
  • EPS Growth
  • TSLX N/A
  • MESO N/A
  • EPS
  • TSLX 2.03
  • MESO N/A
  • Revenue
  • TSLX $482,526,000.00
  • MESO $5,902,000.00
  • Revenue This Year
  • TSLX N/A
  • MESO $140.44
  • Revenue Next Year
  • TSLX N/A
  • MESO $318.31
  • P/E Ratio
  • TSLX $11.58
  • MESO N/A
  • Revenue Growth
  • TSLX 10.14
  • MESO N/A
  • 52 Week Low
  • TSLX $19.50
  • MESO $1.91
  • 52 Week High
  • TSLX $23.66
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • TSLX 80.47
  • MESO 39.05
  • Support Level
  • TSLX $21.93
  • MESO $18.00
  • Resistance Level
  • TSLX $23.15
  • MESO $18.49
  • Average True Range (ATR)
  • TSLX 0.34
  • MESO 0.82
  • MACD
  • TSLX 0.09
  • MESO -0.41
  • Stochastic Oscillator
  • TSLX 90.20
  • MESO 1.75

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: